Kim Nae Yu, Pyo Jung-Soo
Department of Internal Medicine, Eulji University Hospital, Eulji University School of Medicine, Daejeon 35233, Republic of Korea; Study Group for Meta-Analysis, Eulji University Hospital, Eulji University School of Medicine, Daejeon 35233, Republic of Korea.
Department of Pathology, Eulji University Hospital, Eulji University School of Medicine, Daejeon 35233, Republic of Korea; Study Group for Meta-Analysis, Eulji University Hospital, Eulji University School of Medicine, Daejeon 35233, Republic of Korea.
Pathol Res Pract. 2017 Jul;213(7):778-782. doi: 10.1016/j.prp.2017.04.002. Epub 2017 Apr 20.
The aim of this study was to investigate the clinicopathological characteristics and prognostic role of enhancer of zeste homologue 2 (EZH2) expression in non-small cell lung cancer (NSCLC).
The correlation between EZH2 expression and the clinicopathological characteristics, including sex, smoking history, tumor differentiation, histologic type, tumor stage, and lymph node metastasis, was evaluated through a meta-analysis. In addition, the prognostic value of EZH2 expression was elucidated. This study included 1,932 patients with NSCLC from 11 eligible studies.
The overall rate of EZH2 expression was 0.548 [95% confidence interval (CI) 0.491-0.604]. There were significant correlations between EZH2 expression and male sex and smoking history. The expression rate of EZH2 was significantly lower in adenocarcinoma than in other histologic types. Furthermore, EZH2 expression rates were higher in NSCLC with moderately and poorly differentiation and nodal disease than in well-differentiated NSCLC without nodal disease. There was a significant correlation between EZH2 expression and worse overall and disease-free survival [hazard ratio (HR) 1.938, 95% CI 1.617-2.323 and HR 1.713, 95% CI 1.366-2.149, respectively]. Subgroup analysis revealed no significant difference for the prognostic effect of EZH2 expression between histologic types or detection methods.
Our data collectively suggest that EZH2 expression is significantly correlated with aggressive tumor behavior and poor prognosis in NSCLC.
本研究旨在探讨zeste同源物2增强子（EZH2）表达在非小细胞肺癌（NSCLC）中的临床病理特征及预后作用。
通过荟萃分析评估EZH2表达与临床病理特征之间的相关性，这些特征包括性别、吸烟史、肿瘤分化程度、组织学类型、肿瘤分期和淋巴结转移。此外，还阐明了EZH2表达的预后价值。本研究纳入了来自11项符合条件研究的1932例NSCLC患者。
EZH2表达的总体率为0.548[95%置信区间（CI）0.491 - 0.604]。EZH2表达与男性性别和吸烟史之间存在显著相关性。腺癌中EZH2的表达率明显低于其他组织学类型。此外，与无淋巴结疾病的高分化NSCLC相比，中低分化且有淋巴结疾病的NSCLC中EZH2表达率更高。EZH2表达与较差的总生存期和无病生存期显著相关[风险比（HR）分别为1.938，95%CI 1.617 - 2.323和HR 1.713，95%CI 1.366 - 2.149]。亚组分析显示，EZH2表达的预后效应在组织学类型或检测方法之间无显著差异。
我们的数据共同表明，EZH2表达与NSCLC中的侵袭性肿瘤行为和不良预后显著相关。
